Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
45 hedge funds and large institutions have $109M invested in Sigilon Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 17 closing their positions.
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 52 → 45 (-7)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
48% less capital invested
Capital invested by funds: $209M → $109M (-$99.8M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $246K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.99M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.36M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$940K |
| 4 |
Millennium Management
New York
|
+$905K |
| 5 |
State Street
Boston,
Massachusetts
|
+$582K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.66M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.87M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.34M |
| 4 |
ZDA
Zweig-DiMenna Associates
New York
|
-$1.27M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$909K |
SGTX Hedge Fund Activity: Q3 2021 in Review
45 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q3 2021, worth a combined $109M — down 48% from $209M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SGTX and 10 opened new positions — a net loss of 7 holders — while 7 trimmed existing stakes and 20 added.
The largest buyer was BlackRock, adding an estimated $1.99M. The largest seller was Wellington Management Group, exiting entirely with an estimated $6.66M sold.
- 45 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q3 2021, down from 52 in Q2 2021.
- Funds reported $109M of Sigilon Therapeutics, Inc. Common Stock stock for Q3 2021, down 48% quarter-over-quarter.
- 10 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q3 2021 and 17 closed out, a net change of -7 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q3 2021 was BlackRock, an estimated $1.99M added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q3 2021 was Wellington Management Group, an estimated $6.66M sold.
Based on aggregated 13F filings for Q3 2021.